Ultragenyx治疗遗传性骨病药物后期临床试验失败

Core Viewpoint - Ultragenyx Pharmaceutical announced that its investigational drug for a specific genetic bone disease did not meet the primary efficacy endpoint in late-stage clinical trials [1] Group 1 - The investigational drug is aimed at treating a specific genetic bone disease [1] - The announcement was made on a Monday [1] - The failure to meet the primary efficacy endpoint occurred during late-stage clinical trials [1]